MNPR-101-DFO*-89Zr Expanded Access Program (EAP) for Patients With Solid Tumor Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this Expanded Access Program (EAP) is to allow use of the investigational imaging agent, MNPR-101-DFO\*-89Zr, with positron emission tomography/computed tomography (PET/CT) imaging, to non-invasively detect the presence of urokinase plasminogen activator receptor (uPAR) binding in solid tumors. uPAR binding is higher in tumors compared to normal tissue in some cancers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors

NCT06337084

Solid Tumor, Adult Bladder Cancer Urothelial Carcinoma +6 more

RECRUITING PHASE1

68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

NCT02038738

Neuroendocrine Neuroendocrine Tumor Neuroendocrine Cancer +5 more

UNKNOWN PHASE1/PHASE2

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

NCT01806675

Adult Giant Cell Glioblastoma Adult Glioblastoma Adult Gliosarcoma +41 more

COMPLETED PHASE1/PHASE2

PET [89Zr]DFO-starPEG in Solid Tumors

NCT06894745

Solid Tumor Solid Carcinoma Soft Tissue Lesion

RECRUITING PHASE1

Diagnosis of Metastatic Tumors on 68Ga-FAPI PET-CT and Radioligand Therapy with 177Lu-EB-FAPI

NCT05400967

177Lu-EB-FAPI

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Imaging agent MNPR-101-DFO\*-89Zr will be dosed to adult patients diagnosed with solid tumor cancer followed 3 to 5 days later by PET/CT imaging. The result will determine if there is sufficient uPAR binding, as assessed by the Investigator, to support administration of the companion intervention MNPR-101-PCTA-177Lu in a separate expanded access program (EAP IST-00Cb). The safety of MNPR-101-DFO\*-89Zr will be evaluated as will the amount of radioactivity present in blood samples.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Solid Tumor Solid Tumor, Adult

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MNPR-101-DFO*-89Zr

MNPR-101-DFO\*-89Zr is an antibody radionuclide conjugate intended to image solid tumors expressing uPAR.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed locally advanced or metastatic solid tumor cancer that is refractory to existing therapy(ies) known to provide clinical benefit, or for which no standard treatment is available, or is contraindicated
* Ability to understand and willingness to sign a written informed consent document

Exclusion Criteria

* Continuing ≥ Grade 3 adverse reactions from prior systemic therapy (Common Terminology Criteria for Adverse Events \[CTCAE\] version 5.0)
* Prior treatment with any radiopharmaceutical or investigational agents within 4 weeks or 5 half-lives, whichever is longer, prior to administration of MNPR-101-DFO\*-89Zr
* Evidence of impaired organ function, particularly bone marrow, liver, kidney, or heart, according to specific test parameters
* Presence of other serious, non-malignant diseases or any other condition that, in the opinion of the investigator, could interfere with the objectives of the study, participant safety, or compliance.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No